ClinicalTrials.gg
CompletedNCT05277350Updated May 17, 2023

A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects

A Phase 1 interventional study of SNIPR001 and Placebo in E.Coli Infections and Bloodstream Infection, sponsored by SNIPR Biome Aps.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-17.

Sponsored by SNIPR Biome Aps. · Phase 1, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was Nov 2022, 3 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 517 studies in Sepsis with a site in United States — 74 open to participants now, 99 under way, 3 of them phase 3. Sepsis · United States.

Enrollment
213th of 310
36 · median 84
Started
2022
with 23 others
Phase 1
32 of 517
3 open now
Registered
409th of 517
by date

Among the 517 studies in Sepsis with a site in United States, this one is the 213th largest by enrollment of the 310 interventional ones that give a count, is one of 24 that started in 2022, is one of 32 in phase 1, and was the 409th registered.

Sepsis

2,421 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

74 of the 517 studies in Sepsis with a site in United States are open now. Recruiting first, the newest first:

69 more — sign in →

All 74 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 517 studies in Sepsis with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1, randomized, double-blind, placebo-controlled, multiple dose, dose escalation study in healthy participants, investigating the safety, tolerability, recovery, and PD of multiple oral administrations of SNIPR001.

Read the detailed description

Approximately 36 healthy male and female participants will be randomized to one of 3 active oral doses of SNIPR001 or matching placebo, administered twice a day (BID) for 7 days. Subjects will be followed up until 6 months after receiving the last dose of SNIPR001.

03

Conditions studied

  • E.Coli Infections
  • Bloodstream Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Male or female healthy subject defined as no known organ abnormality, or disease diagnosis, as per Investigator discretion
  • No clinically significant abnormalities indicated by safety laboratory test results
  • Age between 18 years and 65 years
  • E. coli present in feces sample
  • Normal defecation pattern (at least once daily)
  • Willing to participate in the study and provide fecal samples

Exclusion criteria

Exclusion Criteria:

  • Treatment with antibiotics or any other prescription medication within the last 30 days prior to or during screening
  • Use of probiotics (not including dairy products) within the last 30 days prior to or during screening
  • Smoking (cigarettes, pipes, vaping products, etc.) within the last 3 months prior to or during screening
  • 6 months prior to or during screening, recent history of alcohol or drug abuse, or current regular alcohol consumption of more than 14 units per week (one unit of alcohol equals one beer (285 ml), one glass of wine (125 ml), or one glass of spirits (25 ml))
  • Positive alcohol or drugs of abuse test
  • Pregnancy or lactating or intention of becoming pregnant (all females to agree to use highly effective (defined as those, alone or in combination, that result in a low failure rate i.e., less than 1% per year) for the entire study duration
  • Obesity as defined by WHO i.e., >32 kg/m2
  • Known to be -positive
  • Known active and/or infection
  • Known congenital or acquired immunodeficiency
  • Allergy to any component of the trial drug and ant-acid treatment
  • Regular use of medications that affect gastrointestinal motility e.g., antidiarrheals, stool softeners and laxatives, GLP-1 analogues
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Active comparator
    Cohort 1

    6 participants on SNIPR001 (Dose 1 BID for 7 days) and 2 participants on placebo

    Drug: SNIPR001 · Drug: Placebo

  • Active comparator
    Cohort 2

    6 participants on SNIPR001 (Dose 2 BID for 7 days) and 2 participants on placebo

    Drug: SNIPR001 · Drug: Placebo

  • Active comparator
    Cohort 3

    12 participants on SNIPR001 (Dose 3 BID for 7 days) and 8 participants on placebo

    Drug: SNIPR001 · Drug: Placebo

Interventions

  • DrugSNIPR001

    SNIPR001 is a live biotherapeutic product consisting of genetically modified bacteriophages specifically targeting Escherichia coli

  • DrugPlacebo

    Matching placebo

06

What researchers measure

Primary outcomes

  1. Safety and tolerability as measured by incidence and severity of AEs and Medically Attended Adverse Events (MAAEs) from the first administration of study drug and up until Day 35 of the study.

    Time frame: 35 days

Secondary outcomes

  1. Incidence and severity of AEs and MAAEs from Day 35 to Day 187 of the study

    Time frame: 152 days

  2. Functional quantification of SNIPR001 (recovery) in feces, blood, and urine before, during, and after multiple oral SNIPR001 administrations

    Time frame: 187 days

07

Study locations

1 site
  • Medpace Clinical Pharmacology
    Cincinnati, Ohio 45227, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Nov 2022, 8 months.

Of 33 phase 1 interventional studies under Sepsis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2022
First posted
Mar 14, 2022
StartActual
Mar 24, 2022
Primary completionActual
Nov 30, 2022
CompletionActual
May 1, 2023
Last update
May 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05277350
Lead sponsor
SNIPR Biome Aps.
Collaborators
Biomedical Advanced Research and Development Authority, Wellcome Trust
Responsible party
Sponsor
First posted
Mar 14, 2022
Start date
Mar 24, 2022
Primary completion
Nov 30, 2022
Completion
May 1, 2023
Last update
May 17, 2023

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion